Treatment of Locally Advanced Non–Small Cell Lung Cancer

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Locally advanced non–small cell lung cancer is a heterogeneous disease with typically poor outcomes. Select patients may benefit from the integration of surgery, whereas patients with bulky, multistation, or contralateral (N3) mediastinal involvement are managed with definitive chemoradiation. Attempts to improve outcomes through induction, consolidation, or maintenance chemotherapy or radiation dose escalation have not demonstrated a survival benefit. Current research efforts focus on the integration of novel systemic agents that exploit tumor-specific driver mutations, augment antitumor immune response, or enhance radiation sensitivity.

Original languageEnglish (US)
Pages (from-to)45-57
Number of pages13
JournalHematology/Oncology Clinics of North America
Volume31
Issue number1
DOIs
StatePublished - Feb 1 2017

Fingerprint

Non-Small Cell Lung Carcinoma
Consolidation Chemotherapy
Maintenance Chemotherapy
Induction Chemotherapy
Radiation Tolerance
Radiation
Mutation
Survival
Therapeutics
Research
Neoplasms

Keywords

  • Chemoradiation
  • Locally advanced disease
  • Non–small cell lung cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Treatment of Locally Advanced Non–Small Cell Lung Cancer. / Tam, Kit; Daly, Megan E; Kelly, Karen.

In: Hematology/Oncology Clinics of North America, Vol. 31, No. 1, 01.02.2017, p. 45-57.

Research output: Contribution to journalReview article

@article{f73ecc23c45c417899ee8d7aac30cf94,
title = "Treatment of Locally Advanced Non–Small Cell Lung Cancer",
abstract = "Locally advanced non–small cell lung cancer is a heterogeneous disease with typically poor outcomes. Select patients may benefit from the integration of surgery, whereas patients with bulky, multistation, or contralateral (N3) mediastinal involvement are managed with definitive chemoradiation. Attempts to improve outcomes through induction, consolidation, or maintenance chemotherapy or radiation dose escalation have not demonstrated a survival benefit. Current research efforts focus on the integration of novel systemic agents that exploit tumor-specific driver mutations, augment antitumor immune response, or enhance radiation sensitivity.",
keywords = "Chemoradiation, Locally advanced disease, Non–small cell lung cancer",
author = "Kit Tam and Daly, {Megan E} and Karen Kelly",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.hoc.2016.08.009",
language = "English (US)",
volume = "31",
pages = "45--57",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Treatment of Locally Advanced Non–Small Cell Lung Cancer

AU - Tam, Kit

AU - Daly, Megan E

AU - Kelly, Karen

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Locally advanced non–small cell lung cancer is a heterogeneous disease with typically poor outcomes. Select patients may benefit from the integration of surgery, whereas patients with bulky, multistation, or contralateral (N3) mediastinal involvement are managed with definitive chemoradiation. Attempts to improve outcomes through induction, consolidation, or maintenance chemotherapy or radiation dose escalation have not demonstrated a survival benefit. Current research efforts focus on the integration of novel systemic agents that exploit tumor-specific driver mutations, augment antitumor immune response, or enhance radiation sensitivity.

AB - Locally advanced non–small cell lung cancer is a heterogeneous disease with typically poor outcomes. Select patients may benefit from the integration of surgery, whereas patients with bulky, multistation, or contralateral (N3) mediastinal involvement are managed with definitive chemoradiation. Attempts to improve outcomes through induction, consolidation, or maintenance chemotherapy or radiation dose escalation have not demonstrated a survival benefit. Current research efforts focus on the integration of novel systemic agents that exploit tumor-specific driver mutations, augment antitumor immune response, or enhance radiation sensitivity.

KW - Chemoradiation

KW - Locally advanced disease

KW - Non–small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84998879861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998879861&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2016.08.009

DO - 10.1016/j.hoc.2016.08.009

M3 - Review article

VL - 31

SP - 45

EP - 57

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 1

ER -